Aquestive Therapeutics (AQST) Short term Debt: 2018-2025
Historic Short term Debt for Aquestive Therapeutics (AQST) over the last 6 years, with Sep 2025 value amounting to $6.3 million.
- Aquestive Therapeutics' Short term Debt rose 25208.00% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 25208.00%. This contributed to the annual value of $26,000 for FY2024, which is 18.18% up from last year.
- Per Aquestive Therapeutics' latest filing, its Short term Debt stood at $6.3 million for Q3 2025, which was up 99.15% from $3.2 million recorded in Q2 2025.
- Over the past 5 years, Aquestive Therapeutics' Short term Debt peaked at $18.7 million during Q4 2022, and registered a low of $22,000 during Q4 2023.
- In the last 3 years, Aquestive Therapeutics' Short term Debt had a median value of $27,000 in 2025 and averaged $4.5 million.
- In the last 5 years, Aquestive Therapeutics' Short term Debt crashed by 99.88% in 2023 and then spiked by 25,208.00% in 2025.
- Over the past 5 years, Aquestive Therapeutics' Short term Debt (Quarterly) stood at $2.0 million in 2021, then surged by 823.46% to $18.7 million in 2022, then tumbled by 99.88% to $22,000 in 2023, then rose by 18.18% to $26,000 in 2024, then spiked by 25,208.00% to $6.3 million in 2025.
- Its last three reported values are $6.3 million in Q3 2025, $3.2 million for Q2 2025, and $27,000 during Q1 2025.